Condition
Resectable Head and Neck Squamous-cell Carcinoma
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Unknown1
Not Yet Recruiting1
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07630168Phase 2Not Yet Recruiting
Effects of Infusion Timing on Treatment Response in Solid Tumors
NCT06997094Phase 1Recruiting
Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer
NCT06235918Phase 2Unknown
Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma
Showing all 3 trials